fda removes tirzepatide Compounding pharmacies can resume making as reconsiders shortage FDA's tirzepatide decision creates uncertainty

Louis Aronne, director of comprehensive weight control center, Weill Cornell Medicine

She also encouraged people to speak to a medical provider first about the weight-loss treatments, and to use the medications responsibly

Switching from off-label Ozempic for weight loss to these approved options can improve your insurance approval odds, as insurers like Aetna and others are more likely to cover therapies aligned with FDA-approved indications

GLP-1 weight loss injections offer a less invasive alternative

When Ozempic or Mounjaro face supply constraints, compounded alternatives remain available because they source active pharmaceutical ingredients through separate supply chains

However, it will not go away completely